These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
566 related articles for article (PubMed ID: 15800138)
1. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138 [TBL] [Abstract][Full Text] [Related]
2. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ; Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420 [TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748 [TBL] [Abstract][Full Text] [Related]
4. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Csernansky JG; Wang L; Miller JP; Galvin JE; Morris JC Arch Neurol; 2005 Nov; 62(11):1718-22. PubMed ID: 16286546 [TBL] [Abstract][Full Text] [Related]
5. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Wang L; Harms MP; Staggs JM; Xiong C; Morris JC; Csernansky JG; Galvin JE Arch Neurol; 2010 Jan; 67(1):99-106. PubMed ID: 20065136 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study. Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669 [TBL] [Abstract][Full Text] [Related]
8. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease. Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762 [TBL] [Abstract][Full Text] [Related]
9. The potentially protective effect of donepezil in Alzheimer's disease. Ishiwata A; Mizumura S; Mishina M; Yamazaki M; Katayama Y Dement Geriatr Cogn Disord; 2014; 38(3-4):170-7. PubMed ID: 24732387 [TBL] [Abstract][Full Text] [Related]
10. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. Kim SH; Kandiah N; Hsu JL; Suthisisang C; Udommongkol C; Dash A Br J Pharmacol; 2017 Dec; 174(23):4224-4232. PubMed ID: 28901528 [TBL] [Abstract][Full Text] [Related]
11. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Dong H; Yuede CM; Coughlan CA; Murphy KM; Csernansky JG Brain Res; 2009 Dec; 1303():169-78. PubMed ID: 19799879 [TBL] [Abstract][Full Text] [Related]
12. Donepezil for severe Alzheimer's disease. Allsop D; Martin FL; Moore S; Fullwood NJ; Lancet; 2006 Jul; 368(9533):361; author reply 362. PubMed ID: 16876652 [No Abstract] [Full Text] [Related]
13. Do lesions involving the cortical cholinergic pathways help or hinder efficacy of donepezil in patients with Alzheimer's disease? Fukui T; Hieda S; Bocti C Dement Geriatr Cogn Disord; 2006; 22(5-6):421-31. PubMed ID: 16974095 [TBL] [Abstract][Full Text] [Related]
14. Vitamin E and donepezil for the treatment of mild cognitive impairment. Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ; N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. Prvulovic D; Schneider B Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1039-50. PubMed ID: 24785550 [TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
17. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542 [TBL] [Abstract][Full Text] [Related]
18. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan. Arai H; Sumitomo K; Sakata Y; Daidoji K; Takase T; Toyoda T Psychogeriatrics; 2016 Mar; 16(2):107-15. PubMed ID: 26114729 [TBL] [Abstract][Full Text] [Related]
19. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032 [TBL] [Abstract][Full Text] [Related]
20. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]